Fortitude Family Office’s TG Therapeutics TGTX Stock Holding History

Fortitude Family Office’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8	Closed	-$238	–	2073
2025 Q4	$238	Buy	+8	New	+$261	﹤0.01%	1854

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Fortitude Family Office's TGTX Position: Q1 2026 in Review

Fortitude Family Office sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 8 shares — an estimated $238 sold.

Fortitude Family Office first reported a position in TGTX in Q4 2025 and held it in 1 quarter. The position peaked at $238 in Q4 2025. 364 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Fortitude Family Office reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
Fortitude Family Office sold 8 TG Therapeutics shares in Q1 2026, an estimated $238.
Fortitude Family Office first reported a position in TG Therapeutics in Q4 2025 and held it in 1 quarter.
Fortitude Family Office's TG Therapeutics position peaked at $238 in Q4 2025.
364 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.